Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,195.00 Price Target at Piper Sandler

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by research analysts at Piper Sandler from $1,242.00 to $1,195.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective would suggest a potential upside of 41.65% from the stock’s current price.

A number of other brokerages have also recently commented on REGN. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 22nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,090.24.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $843.60 on Friday. Regeneron Pharmaceuticals has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The stock’s 50 day simple moving average is $1,058.43 and its two-hundred day simple moving average is $1,039.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.62 and a current ratio of 5.99. The stock has a market cap of $93.00 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 2.88 and a beta of 0.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 EPS. As a group, analysts expect that Regeneron Pharmaceuticals will post 37.46 earnings per share for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $28,000. Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $33,000. Finally, Family Firm Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $33,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.